Rethinking Youth Gender Medicine with Dr Louise Irvine
18 June 2026
With Dr Louise Irvine
UK
Dr Louise Irvine, GP and Co-Chair of the Clinical Advisory Network on Sex and Gender, joins the podcast ahead of CAN-SG's July 2026 London conference to take stock of paediatric gender medicine in the United Kingdom. The discussion spans the evidentiary failures identified by the Cass Review, the WellBN clinic investigation, the contested design of the NHS puberty blocker clinical trial, and the data linkage infrastructure that would be needed to generate defensible long-term outcome data. A clinically grounded examination of how institutions lost their scepticism and what restoring it requires.
Dr Louise Irvine is a British General Practitioner, GP trainer, and Co-Chair of the Clinical Advisory Network on Sex and Gender (CAN-SG). She joins the Beyond Gender hosts ahead of a CAN-SG conference in London—Rethinking Youth Gender Medicine—to review how paediatric gender medicine developed in the United Kingdom, where it went wrong, and what a responsible clinical path forward might look like. The conversation is grounded in her dual experience as a frontline clinician and a national clinical advocate. A recurring theme is how British institutions came to adopt practices that lacked adequate evidential grounding. Irvine describes a process by which ideological commitments displaced clinical scepticism inside bodies including the NHS. Research barriers, she argues, were constructed around paediatric gender services that made external scrutiny difficult while referrals expanded rapidly—a dynamic consistent with the Cass Review's finding that the evidence base underpinning almost every category of gender-affirming intervention for under-18s was of low or very low quality. The WellBN clinic investigation features prominently. WellBN operated as a private provider outside the NHS pathway, and its investigation raises questions about clinical governance and whether regulatory structures kept pace with the proliferation of gender services in the years before the Cass Review. Irvine's experience as a practising GP provides a grounded account of what patients and families encountered when they reached services that may have lacked adequate safeguarding and diagnostic rigour. Discussion of the NHS puberty blocker clinical trial is timely. After NHS England banned puberty blockers for gender dysphoria outside a research setting, a trial framework was proposed—but its design remains contested. The episode addresses what conditions would need to be met for a trial to produce meaningful data: extended follow-up periods, outcome measures beyond short-term self-reported wellbeing, and infrastructure capable of genuine scientific oversight. The concept of tooth fairy science receives sustained attention. The phrase—associated with critical analysis of gender medicine research methodology—describes studies that accurately measure a narrow outcome while systematically avoiding the causally relevant question. Applied to this field, it captures research that records short-term quality-of-life scores without establishing whether an intervention improves long-term psychiatric outcomes or reduces the risk of medical harm. The episode uses this frame to distinguish between what has been studied and what would actually need to be known before clinical guidance could be considered evidence-based. The episode closes on data linkage—the systematic connection of health records across NHS systems to track long-term outcomes for people who accessed gender services. This methodological step, Irvine argues, is the prerequisite for the population-level evidence that has been absent throughout a decade of clinical expansion. The CAN-SG conference represents a coalition of clinicians insisting that robust longitudinal data is not a future aspiration but the minimum requirement for any defensible guidance.
